Stock Price Forecast

Feb. 12, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Immunogen, Inc. chart...

About the Company

immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.

CEO

Mark Enyedy

Exchange

NASDAQ

Website

http://www.immunogen.com/

$8M

Total Revenue

373

Employees

$8B

Market Capitalization

-53.15

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $IMGN News

ImmunoGen files patent for combination therapy for hematological malignancies using immunoconjugates

6d ago, source: Pharmaceutical Technology

Discover ImmunoGen Inc.'s groundbreaking patent for innovative immunoconjugate therapies targeting CD123 in hematologic malignancies. Learn about effective treatments with reduced toxicity and methods ...

AbbVie ends stay with the ADAM family, dropping MacroGenics-partnered ADC in light of early data

10d ago, source: FierceBiotech

AbbVie has cut short its call on the ADAM family. The ADAM9-targeted antibody-drug conjugate MGC936 fell short of safety and ...

Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?

3d ago, source: Zacks.com on MSN

Looking for broad exposure to the Mid Cap Growth segment of the US equity market? You should consider the First Trust Mid Cap Growth AlphaDEX ETF (FNY), a passively managed exchange traded fund ...

MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript

4d ago, source: InvestingChannel on MSN

March 7, 2024 MacroGenics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ...

New study explores next-generation vaccine technology for RSV

on MSN ago, source:

Calder Biosciences, Inc., a next-generation vaccine company, has published an article that debuts and validates the ...

AbbVie: Strong Cash Flow Growth Fuels Dividend Growth

10d ago, source:

AbbVie is a leading pharmaceutical company with a strong growth history and diverse pipeline. Click here to read an analysis ...

MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

11d ago, source:

Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation ...

100 Stocks You Should Have Invested In 5 Years Ago

13d ago, source:

If you know even a little bit about finance and investing, then you probably know that the stock market offers the most ...

Antibody Drug Conjugate Market Projected to Grow at 12.1% CAGR, Crossing US$ 28.0 Billion by 2033, Reports Marketresearch.biz

4d ago, source: PharmiWeb

Marketresearch.biz reports that the antibody-drug conjugate market was valued at USD 9.2 billion in 2023. It is expected to ...

Calder Biosciences Inc. Publishes Next-Generation Vaccine Technology in Nature Communications

4d ago, source:

Calder Biosciences, Inc., a next-generation vaccine company, has been published in a Nature Communications article ( that debuts and validates the application of Calder's '3D Vaxlock' platform ...

AbbVie Stock: I Was So Wrong, But This Is Way Too Fast

9d ago, source:

AbbVie Inc.'s ability to overcome challenges, strong revenue growth, and reduced risks make investors optimistic. Click for ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...